Home > Neurology > EAN 2020 > Epilepsy > Cenobamate effective in focal epilepsy

Cenobamate effective in focal epilepsy

Data from 2 international, double-blind, placebo-controlled trials showed that cenobamate, a voltage-gated sodium channel blocker, has consistent, statistically significant, and clinically meaningful antiepileptic efficacy [1]. Treatment-emergent adverse events (AEs) were dose dependent and generally mild or moderate.

The 2 pivotal trials were named C013 and C017. They enrolled adult patients with uncontrolled focal onset seizures (FOS) with ≥3 seizures per month (C013) or ≥8 seizures per 8 weeks (C017). Participants also used 1-3 concomitant anti-epileptic drugs. In C013 they were randomised to cenobamate 200 mg/day or placebo; in C017 to cenobamate 100, 200, or 400 mg/day, or placebo. Response was defined as ≥50% reduction in seizure frequency from baseline.

In C013, responder rate in the maintenance phase was significantly h...

please login to read the entire article:

You need to register to read the entire article, please do so now.

Posted on